Skip to content
Original
mp.weixin.qq.com·· 2 days agoScore80

Bayer Finerenone FIND-CKD Subgroup Analyses Show Kidney Protection in FSGS and IgAN Patients

In brief

At the 2026 ASN Kidney Week, Bayer presented two subgroup analyses of the FIND-CKD trial showing that finerenone reduced proteinuria and slowed eGFR decline in both FSGS and IgAN patients with non-diabetic chronic kidney disease.

Source: mp.weixin.qq.com · mp.weixin.qq.com

#Clinical readout#Cardiometabolic
CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.